Tempus AI (TEM) has launched a new prostate test for metastatic hormone-sensitive prostate cancer patients, the company said Thursday.
The ArteraAI prostate test uses artificial intelligence to assess a patient's clinical data and biopsy images to estimate a patient's likelihood of prostate cancer-specific mortality, Tempus AI said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments